RecruitingPhase 1NCT06063681

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors

Sponsor

Stingray Therapeutics

Enrollment

25 participants

Start Date

Oct 12, 2023

Study Type

INTERVENTIONAL

Conditions

Advanced / Metastatic Solid Tumor

Summary

This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Immune checkpoint inhibitor (ICI) and a drug called SR-8541A for people with advanced / metastatic solid tumor. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSR-8541A

orally administered ENPP1 inhibitor

DRUGImmune checkpoint inhibitor (ICI)

The ICI will be either nivolumab or pembrolizumab.

Locations(3)

Scientia Clinical Research Ltd

Randwick, New South Wales, Australia

Monash Health

Clayton, Victoria, Australia

Peninsula & South Eastern Haematology & Oncology Group

Frankston, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06063681

Related Trials

Study of ABO2102 in KRAS-Mutated Solid Tumors

NCT074556171 location